In Vitro Activities of Peptide Deformylase Inhibitors against Gram-Positive Pathogens
Open Access
- 1 April 2002
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 46 (4), 1117-1118
- https://doi.org/10.1128/aac.46.4.1117-1118.2002
Abstract
The activities of six peptide deformylase (PDF) inhibitors against 107 respiratory tract pathogens were studied and compared to those of ciprofloxacin and amoxicillin-clavulanate. Against Streptococcus pneumoniae , BB-83698 and BB-83815 were the most active PDF inhibitors (MIC at which 90% of the organisms tested were inhibited [MIC 90 ], 0.25 μg/ml). Five of the agents showed similar activity against Moraxella catarrhalis (MIC 90 , 0.12 μg/ml). All PDF inhibitors were less active against Haemophilus influenzae ; BB-3497 was the most active agent (MIC 90 , 2 μg/ml). Five agents were studied against Chlamydia spp. and showed activity similar to that of ciprofloxacin (MIC, 0.5 to 4 μg/ml). This study demonstrates that PDF inhibitors have the potential to be developed for the treatment of respiratory tract infections.Keywords
This publication has 3 references indexed in Scilit:
- Antibiotic Activity and Characterization of BB-3497, a Novel Peptide Deformylase InhibitorAntimicrobial Agents and Chemotherapy, 2001
- The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinoloneJournal of Antimicrobial Chemotherapy, 1999
- Commercially available fluorescein-conjugated monoclonal antibody for determining the in vitro activity of antimicrobial agents againstChlamydia trachomatisEuropean Journal of Clinical Microbiology & Infectious Diseases, 1987